SOME CHARACTERISTICS OF THE COURSE OF CORONARY HEART DISEASE WITH A COMORBID PATHOLOGY
Nowadays, scientists and doctors are increasingly paying attention to the study of the cardinal problem of modern clinical medicine, comorbidity and polymorbidity, which may arise as a result of common etiology, pathogenesis, cause and effect influences (the syntopic impairments) or as an accidental combination of disease (the accompanying impairments) with age factor, anatomical closeness of the affected organs or accidental combination of diseases. The aim: to define the concomitant diseases and their course, which are most often observed in patients with CHD. The prospective study involved 100 patients with coronary heart disease: stable angina, І-ІV NYHA Class, І-II HF. Results and discussion. The incidence of combined pathology in patients with CHD increases with age: in group I, one of the comorbid conditions prevails (mainly gastrointestinal tract diseases), in group II and III, there are two or more concomitant diseases. Among the total number of patients, 95% live in the city, hence the result of the urbanization process, and only 5% live in the village. The analysis of medicines prescriptions, used in the treatment of patients with CHD revealed an increased use of larger amounts of drugs in age group III (≥60) as compared to groups I (≤40) and II (41-60). Adequate combined prescriptions of medicines to patients with comorbid conditions will allow us not only to prevent progression of each disease, but also to improve the long-term prognosis. Essential hypertension is the «leader» in the total number of comorbid diseases, which makes up 77% of patients among the total number of subjects, with the highest incidence in the II (41-60) and III (≥60) age group. Thus, the obtained results indicate differences in the course and clinical presentation of coronary heart disease, depending on the presence of comorbid pathology, which leads to a more severe disease course, a greater number of comorbidities with increasing age of patients.
2. Drangoy M.G. Age-related diseases. Exmo, Moscow 2007; 738-739
3. Caughey G.E., Roughead E.E. Multimorbidity research challenges: where to go from here? Journal of Comorbidity 2011; 1: 8–9.
4. Mercer S.W., Gunn J., Wyke S. Improving the health of people with multimorbidity: the need for prospective cohort studies. J. Comorbidity, 2011;1: 4–6.
5. Van Weel C., Schellevis F.G. Comorbidity and guidelines: conflicting interests. Lancet 2006;367(9510): 550.
6. Valderas J.M., Starfield B., Sibbald B. et al. Defining Comorbidity: Implications for Understanding Health and Health Services . Ann. Fam. Med. 2009; 7 : 357-363.
7. Lazebnik LB Aging and polymorbidity. Medicine and Pharmacy News 2007; 10–11.
8. Komissarenko IA .Polymorbidity and metabolic syndrome in the elderly. Wedge. gerontology 2009; 15 (1): 29-36.
9. Dawes M. Co-morbidity: we need a guideline for each patient not a guideline for each disease. Fam. Pract. 2010; 27(1): 1–2.
10. Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine. Evid. Based Med., 2010; 15(6): 165–166.
11. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. [Electronic Resource] / WHO, 2011; http://www. goldcopd.com/
12. Shut SV, Chekalina NI, Tribrat TA, Shapovalenko N. Yu Ischemic heart disease and hypertension: features of disorders of central hemodynamics. Medicine of Transport of Ukraine 2010; 1 (33): 47–49.
13. Shut SV, Tribrat TA, Sakevich VD, Goryashchenko TI, et al. Features of the daily profile of blood pressure in patients with hypertension with metabolic syndrome. Bulletin of problems of biology and medicine 2016; 2, 1 (128): 132–134.
14. Vertkin AL, Rumyantsev MA, Scotnikov AS. Comorbidity. Clinical Medicine 2012; 10: 4-10.
15. Pichkhadze GM, Satbaeva EM. The effect of polypragmasia on the severity of adverse effects in elderly patients. Pharmacy of Kazakhstan 2014; 4: 22-23.
16. Mitrofanov IM, Nikolaev Yu, Dolgov NA, Pospelova TI. Regional features of polymobidity in the modern clinic of internal diseases. honey. 2013; 6: 26-29
17. Caughey GE. Roughead EE. Multimorbidity research challenges: where to go from here? J. of Comorbidity 2011;1: 8- 10.
18. Lapach CH. Chubenko AB, Babich MON. Statistical Methods in Biomedical Research Using Exel. Kiev: Morion, 2000; 320
19. Bogoslav TV, Medvedev BB. Peculiarities of vascular changes in young patients with hypertension. Ukrainian Cardiology Journal 2015; 1:28.
20. Treumova SI, Petrov EE, Burmak Yug, Ivanytska TA. Chronic obstructive pulmonary disease and coronary heart disease: problems of comorbidity (literature review). Bulletin of problems in biology and medicine. 2017; 4, 3 (141): 66-72.
This work is licensed under a Creative Commons Attribution 4.0 International License.